{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:50:11Z","timestamp":1786373411697,"version":"build-2736575974"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.2215\/cjn.11331114","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T22:35:17Z","timestamp":1438209317000},"page":"1534-1541","source":"Crossref","is-referenced-by-count":32,"title":["Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00456365","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jelena","family":"Klawitter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"McFann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost","family":"Klawitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Schrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Cadnapaphornchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20230601","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJM199010183231601","article-title":"The diagnosis and prognosis of autosomal dominant polycystic kidney disease.","volume":"323","author":"Parfrey","year":"1990","journal-title":"N Engl J Med"},{"key":"R2-7-20230601","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1046\/j.1523-1755.2001.0590051654.x","article-title":"Progression of autosomal-dominant polycystic kidney disease in children.","volume":"59","author":"Fick-Brosnahan","year":"2001","journal-title":"Kidney Int"},{"key":"R3-7-20230601","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMc061638","article-title":"Volume progression in polycystic kidney disease.","volume":"355","author":"Brosnahan","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-7-20230601","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ki.2008.397","article-title":"Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension.","volume":"74","author":"Cadnapaphornchai","year":"2008","journal-title":"Kidney Int"},{"key":"R5-7-20230601","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2215\/CJN.02810608","article-title":"Prospective change in renal volume and function in children with ADPKD.","volume":"4","author":"Cadnapaphornchai","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-7-20230601","doi-asserted-by":"crossref","first-page":"F854","DOI":"10.1152\/ajprenal.00059.2007","article-title":"Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.","volume":"293","author":"Zafar","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R7-7-20230601","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2369-14-165","article-title":"Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease.","volume":"14","author":"Klawitter","year":"2013","journal-title":"BMC Nephrol"},{"key":"R8-7-20230601","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.","volume":"16","author":"van Dijk","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R9-7-20230601","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cct.2011.01.008","article-title":"Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants.","volume":"32","author":"Cadnapaphornchai","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"R10-7-20230601","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"R11-7-20230601","doi-asserted-by":"crossref","first-page":"F1198","DOI":"10.1152\/ajprenal.00327.2014","article-title":"Endothelial dysfunction and oxidative stress in polycystic kidney disease.","volume":"307","author":"Klawitter","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"R12-7-20230601","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","article-title":"Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis.","volume":"56","author":"Meijer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R13-7-20230601","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2215\/CJN.04140510","article-title":"Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease.","volume":"6","author":"Menon","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-7-20230601","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.ajkd.2007.09.020","article-title":"Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease.","volume":"51","author":"Wang","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R15-7-20230601","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.V1181371","article-title":"Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease.","volume":"11","author":"Wang","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R16-7-20230601","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1194\/jlr.P042176","article-title":"Bioactive lipid mediators in polycystic kidney disease.","volume":"55","author":"Klawitter","year":"2013","journal-title":"J Lipid Res"},{"key":"R17-7-20230601","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ki.2011.465","article-title":"Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.","volume":"81","author":"Parikh","year":"2012","journal-title":"Kidney Int"},{"key":"R18-7-20230601","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents.","volume":"34","author":"Schwartz","year":"1987","journal-title":"Pediatr Clin North Am"},{"key":"R19-7-20230601","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.me.19.020168.001435","article-title":"Growth and physiological development during adolescence.","volume":"19","author":"Marshall","year":"1968","journal-title":"Annu Rev Med"},{"key":"R20-7-20230601","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/adc.44.235.291","article-title":"Variations in pattern of pubertal changes in girls.","volume":"44","author":"Marshall","year":"1969","journal-title":"Arch Dis Child"},{"key":"R21-7-20230601","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/adc.45.239.13","article-title":"Variations in the pattern of pubertal changes in boys.","volume":"45","author":"Marshall","year":"1970","journal-title":"Arch Dis Child"},{"key":"R23-7-20230601","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2215\/CJN.03780410","article-title":"Magnetic resonance imaging of kidney and cyst volume in children with ADPKD.","volume":"6","author":"Cadnapaphornchai","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R24-7-20230601","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"R25-7-20230601","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-7-20230601","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.08940813","article-title":"Renal relevant radiology: Radiologic imaging in autosomal dominant polycystic kidney disease.","volume":"9","author":"Rahbari-Oskoui","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-7-20230601","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2013.03.003","article-title":"Development and validation of an LC-MS\/MS assay for the quantification of the trans-methylation pathway intermediates S-adenosylmethionine and S-adenosylhomocysteine in human plasma.","volume":"421","author":"Klepacki","year":"2013","journal-title":"Clin Chim Acta"},{"key":"R28-7-20230601","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/rcm.3331","article-title":"Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography\/electrospray ionisation tandem mass spectrometry.","volume":"22","author":"Masoodi","year":"2008","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R29-7-20230601","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ki.1983.51","article-title":"Rate of functional deterioration in polycystic kidney disease.","volume":"23","author":"Franz","year":"1983","journal-title":"Kidney Int"},{"key":"R30-7-20230601","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease.","volume":"41","author":"Gabow","year":"1992","journal-title":"Kidney Int"},{"key":"R31-7-20230601","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(01)06531-X","article-title":"Autosomal dominant polycystic kidney disease: Modification of disease progression.","volume":"358","author":"Peters","year":"2001","journal-title":"Lancet"},{"key":"R32-7-20230601","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","article-title":"Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat.","volume":"26","author":"Gile","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"R33-7-20230601","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","article-title":"Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.","volume":"95","author":"O\u2019Driscoll","year":"1997","journal-title":"Circulation"},{"key":"R34-7-20230601","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"R35-7-20230601","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.HYP.37.6.1450","article-title":"HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.","volume":"37","author":"Wassmann","year":"2001","journal-title":"Hypertension"},{"key":"R36-7-20230601","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1053\/j.ajkd.2004.01.011","article-title":"Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease.","volume":"43","author":"Kocaman","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R37-7-20230601","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0005-2760(91)90230-F","article-title":"Stereospecificity of the hydroxyeicosatetraenoic and hydroxyoctadecadienoic acids produced by cultured bovine endothelial cells.","volume":"1085","author":"Baer","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"R38-7-20230601","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0163-7827(96)00008-2","article-title":"Biosynthesis, metabolization and biological importance of the primary 15-lipoxygenase metabolites 15-hydro(pero)XY-5Z,8Z,11Z,13E-eicosatetraenoic acid and 13-hydro(pero)XY-9Z,11E-octadecadienoic acid.","volume":"35","author":"K\u00fchn","year":"1996","journal-title":"Prog Lipid Res"},{"key":"R39-7-20230601","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-2275(20)32149-0","article-title":"13-(S)-hydroxyoctadecadienoic acid (13-HODE) incorporation and conversion to novel products by endothelial cells.","volume":"40","author":"Fang","year":"1999","journal-title":"J Lipid Res"},{"key":"R40-7-20230601","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1681\/ASN.2007080939","article-title":"Products of 12\/15-lipoxygenase upregulate the angiotensin II receptor.","volume":"19","author":"Xu","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R41-7-20230601","doi-asserted-by":"crossref","first-page":"F985","DOI":"10.1152\/ajprenal.00181.2002","article-title":"Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells.","volume":"283","author":"Reddy","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"R42-7-20230601","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1074\/jbc.270.41.23975","article-title":"Differential activation of peroxisome proliferator-activated receptors by eicosanoids.","volume":"270","author":"Yu","year":"1995","journal-title":"J Biol Chem"},{"key":"R43-7-20230601","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ki.1994.374","article-title":"Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.","volume":"46","author":"Barrett","year":"1994","journal-title":"Kidney Int"},{"key":"R44-7-20230601","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.","volume":"323","author":"Chapman","year":"1990","journal-title":"N Engl J Med"},{"key":"R45-7-20230601","doi-asserted-by":"crossref","first-page":"640","DOI":"10.2215\/CJN.03250410","article-title":"Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R46-7-20230601","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1111\/j.1559-4572.2008.00052.x","article-title":"Statin pleiotropy against renal injury.","volume":"4","author":"Kostapanos","year":"2009","journal-title":"J Cardiometab Syndr"},{"key":"R47-7-20230601","first-page":"123","article-title":"The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease.","volume":"7","author":"Gomez","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R48-7-20230601","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1681\/ASN.2005121341","article-title":"Statins and renal diseases: From primary prevention to renal replacement therapy.","volume":"17","author":"D\u2019Amico","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R49-7-20230601","doi-asserted-by":"crossref","first-page":"e16957","DOI":"10.1371\/journal.pone.0016957","article-title":"The human serum metabolome.","volume":"6","author":"Psychogios","year":"2011","journal-title":"PLoS One"},{"key":"R50-7-20230601","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/ajcn\/80.6.1611","article-title":"Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.","volume":"80","author":"James","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"R51-7-20230601","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1194\/jlr.M009449","article-title":"Lipidomics reveals a remarkable diversity of lipids in human plasma.","volume":"51","author":"Quehenberger","year":"2010","journal-title":"J Lipid Res"},{"key":"R52-7-20230601","doi-asserted-by":"crossref","first-page":"e73076","DOI":"10.1371\/journal.pone.0073076","article-title":"The human urine metabolome.","volume":"8","author":"Bouatra","year":"2013","journal-title":"PLoS One"},{"key":"R53-7-20230601","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/clinchem\/40.6.862","article-title":"Age-related reference values for urinary organic acids in a healthy Turkish pediatric population.","volume":"40","author":"Guneral","year":"1994","journal-title":"Clin Chem"},{"key":"R54-7-20230601","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-3476(82)80508-8","article-title":"Urinary prostaglandins, vasopressin, and kallikrein excretion in healthy children from birth to adolescence.","volume":"100","author":"Godard","year":"1982","journal-title":"J Pediatr"},{"key":"R55-7-20230601","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.prostaglandins.2014.08.002","article-title":"Urinary CYP eicosanoid excretion correlates with glomerular filtration in African-Americans with chronic kidney disease.","volume":"113-115","author":"Dreisbach","year":"2014","journal-title":"Prostaglandins Other Lipid Mediat"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201509000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:39Z","timestamp":1786369539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201509000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11331114","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}